Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule API, Small Molecule Drug Product), By Stage Type, By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 3 Business Days
Small Molecule Innovator CDMO Market Growth & Trends
The global small molecule innovator CDMO market size is expected to reach USD 74.9 billion by 2030, expanding at 6.4% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. There is a growing interest among pharmaceutical companies in outsourcing to support core competencies such as sales, marketing, and others, due to associated cost savings. Furthermore, outsourcing enables companies to further progress core competencies such as drug development and manufacturing activities. Hence, expansions by small molecule CDMOs in recent years promise major support for the market growth in the upcoming years.
Small molecules continue to play an important role in the development of new treatments globally. Specialty medicines are increasingly driving global pharmaceutical manufacturing growth, particularly in developed markets with small molecule application accounting for over half of specialty sales. The application of small molecules are becoming increasingly complex.
The majority of solutions in the regulatory approval pipeline are made up of poorly soluble compounds that would require enabling technology to progress to clinical trials and beyond. As therapy targets and focus areas become more specific, creating target product profiles has become increasingly difficult. Failure to achieve appropriate bioavailability is an additional stumbling block in the development of many new chemical entities. These factors are expected to support the overall market growth.
The geriatric population is expected to witness a surge in the coming years. For instance, the WHO estimates that there will be more than 2 billion people aged 60 and over by 2050. This would create a lot of opportunities for the development of new small-molecule drugs, which is expected to support the market growth in the post-pandemic period.
Small Molecule Innovator CDMO Market Report Highlights
Small Molecule Innovator CDMO Market Growth & Trends
The global small molecule innovator CDMO market size is expected to reach USD 74.9 billion by 2030, expanding at 6.4% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. There is a growing interest among pharmaceutical companies in outsourcing to support core competencies such as sales, marketing, and others, due to associated cost savings. Furthermore, outsourcing enables companies to further progress core competencies such as drug development and manufacturing activities. Hence, expansions by small molecule CDMOs in recent years promise major support for the market growth in the upcoming years.
Small molecules continue to play an important role in the development of new treatments globally. Specialty medicines are increasingly driving global pharmaceutical manufacturing growth, particularly in developed markets with small molecule application accounting for over half of specialty sales. The application of small molecules are becoming increasingly complex.
The majority of solutions in the regulatory approval pipeline are made up of poorly soluble compounds that would require enabling technology to progress to clinical trials and beyond. As therapy targets and focus areas become more specific, creating target product profiles has become increasingly difficult. Failure to achieve appropriate bioavailability is an additional stumbling block in the development of many new chemical entities. These factors are expected to support the overall market growth.
The geriatric population is expected to witness a surge in the coming years. For instance, the WHO estimates that there will be more than 2 billion people aged 60 and over by 2050. This would create a lot of opportunities for the development of new small-molecule drugs, which is expected to support the market growth in the post-pandemic period.
Small Molecule Innovator CDMO Market Report Highlights
- The small molecule API segment is anticipated to register the fastest CAGR of 6.7% over the forecast period. This growth can primarily be attributed to the high approval rate of NME small molecules by regulatory agencies
- The clinical stage segment dominated the market with 55.1% of the revenue share in 2022. CDMOs offer specialized expertise, time-saving, and cost-efficiency during clinical procedures. This is expected to augment the segmental growth over the forecast period
- Based on customer type, the pharmaceutical companies segment held the largest share of 93.9% in 2022. The growing focus on pharmaceutical companies to focus on core competencies, such as sales and adoption of expansion strategies by CDMOs for manufacturing small molecule drugs, are promoting the segment’s market growth
- The oncology segment dominated the market with 41.8% of the revenue share in 2022, and it is anticipated to register the fastest CAGR of over 7.0% over the forecast period. A significant number of oncology drugs in the regulatory approval pipeline is one of the major factors supporting the segment’s growth
- Asia Pacific is anticipated to register the fastest CAGR of 7.2% over the forecast period. Due to significantly cheaper manufacturing costs than in North America & Europe and favorable regulations guiding innovation
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Stage Type
1.1.3 Customer Type
1.1.4 Therapeutic Area
1.1.5 Regional Scope
1.1.6 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.5.1 Approaches Used To Estimate The Market Size
1.5.1.1 Approach 1: Region-Wise Market Estimation Using Bottom-Up Approach
1.5.1.2 Approach 2: Parent Market Analysis
1.5.1.3 Approach 3: Commodity Flow (Company Share Analysis)
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 OBJECTIVE - 1:
1.9.2 OBJECTIVE - 2:
1.9.3 OBJECTIVE - 3:
1.9.4 OBJECTIVE - 4:
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Segment Outlook
CHAPTER 3 SMALL MOLECULE INNOVATORS CDMO MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing Demand for Small Molecule Drug
3.2.1.2 Growing Demand for Small Molecules in the Oncology Segment
3.2.1.3 Increasing Pharmaceutical R&D Investments
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent Government Regulations
3.3.2.2 Compliance Issues with Outsourcing
3.3 Small Molecule Innovators CDMO Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTEL Analysis
3.4 Impact of COVID-19 and Reformation Strategies
CHAPTER 4 SMALL MOLECULE INNOVATOR CDMO MARKET: PRODUCT SEGMENT ANALYSIS
4.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
4.2 Small Molecule API
4.2.1 Small Molecule API, 2018 - 2030 (USD Million)
4.3 Small Molecule Drug Product
4.3.1 Small Molecule Drug Product Market, 2018 - 2030 (USD Billion)
4.3.2 Oral Solid Dose
4.3.2.1 Oral Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.3 Semi-Solid Dose
4.3.3.1 Semi-Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.4 Liquid Dose
4.3.4.1 Liquid-Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.5 Others
4.3.5.1 Others Market, 2018 - 2030 (USD Billion)
CHAPTER 5 SMALL MOLECULE INNOVATORS CDMO MARKET: STAGE TYPE SEGMENT ANALYSIS
5.1 Small Molecule Innovators Cdmo: Market Share Analysis, 2022 & 2030
5.2 Preclinical
5.2.1 Preclinical Market, 2018 - 2030 (USD Billion)
5.3 Clinical
5.3.1 Clinical Market, 2018 - 2030 (USD Billion)
5.3.2 Phase I
5.3.2.1 Phase I Market, 2018 - 2030 (USD Billion)
5.3.2.2 Small
5.3.2.2.1 Small Market, 2018 - 2030 (USD Billion)
5.3.2.3 Medium
5.3.2.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.2.4 Large
5.3.2.4.1. Large Market, 2018 - 2030 (USD Billion)
5.3.3 Phase II
5.3.3.1 Phase II Market, 2018 - 2030 (USD Billion)
5.3.3.2 Small
5.3.3.2.1. Small Market, 2018 - 2030 (USD Billion)
5.3.3.3 Medium
5.3.3.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.3.4 Large
5.3.3.4.1. Large Market, 2018 - 2030 (USD Billion)
5.3.4 Phase III
5.3.4.1 Phase III Market, 2018 - 2030 (USD Billion)
5.3.4.2 Small
5.3.4.2.1 Small Market, 2018 - 2030 (USD Billion)
5.3.4.3 Medium
5.3.4.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.4.4 Large
5.3.4.4.1. Large Market, 2018 - 2030 (USD Billion)
5.4 Commercial
5.4.1. Commercial Market, 2018 - 2030 (USD Billion)
CHAPTER 6 SMALL MOLECULE INNOVATORS CDMO MARKET: CUSTOMER TYPE SEGMENT ANALYSIS
6.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
6.2 Pharmaceutical
6.2.1 Pharmaceutical Market, 2018 - 2030 (USD Million)
6.2.2 Small
6.2.2.1 Small Market, 2018 - 2030 (USD Million)
6.2.3 Medium
6.2.3.1 Medium Market, 2018 - 2030 (USD Million)
6.2.4 Large
6.2.4.1 Large Market, 2018 - 2030 (USD Million)
6.3 Biotechnology
6.3.1 Biotechnology Market, 2018 - 2030 (USD Million)
CHAPTER 7 SMALL MOLECULE INNOVATORS CDMO MARKET: THERAPEUTIC AREA SEGMENT ANALYSIS
7.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
7.2 Cardiovascular Disease
7.2.1 Cardiovascular diseases market, 2018 - 2030 (USD Million)
7.3 Oncology
7.3.1 Oncology market, 2018 - 2030 (USD Million)
7.4 Respiratory Disorders
7.4.1 Respiratory disorders market, 2018 - 2030 (USD Million)
7.5 Neurology
7.5.1 Neurology market, 2018 - 2030 (USD Million)
7.6 Metabolic Disorders
7.6.1 Metabolic disorders market, 2018 - 2030 (USD Million)
7.7 Infectious Diseases
7.7.1 Infectious diseases market, 2018 - 2030 (USD Million)
7.8 Others
7.8.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 8 SMALL MOLECULE INNOVATORS CDMO MARKET: REGIONAL ANALYSIS
8.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
8.2 North America
8.2.1 North America Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3 Europe
8.3.1 Europe Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.2 U.K.
8.3.2.1 U.K. Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.3 Germany
8.3.3.1 Germany Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.4 France
8.3.4.1 France Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.5 Italy
8.3.5.1 Italy Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.6 Spain
8.3.6.1 Spain Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.7 Denmark
8.3.7.1 Denmark Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.8 Sweden
8.3.8.1 Sweden Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.9 Norway
8.3.9.1 Norway Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.2 India
8.4.2.1 India Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.3 Japan
8.4.3.1 Japan Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.4 China
8.4.4.1 China Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.5 Australia
8.4.5.1 Australia Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.6 South Korea
8.4.6.1 South Korea Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.7 Thailand
8.4.7.1 Thailand Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5 Latin America
8.5.1 Latin America Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Argentina Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6 MEA
8.6.1 MEA Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.4 UAE
8.6.4.1 UAE Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.5 Kuwait
8.6.5.1 Kuwait Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Company Profiles
9.1.1 Lonza
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Service benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Patheon (Thermo Fisher Scientific)
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Service benchmarking
9.1.2.4 Strategic initiatives
9.1.3 Cambrex Corporation
9.1.3.1 Company overview
9.1.3.2 Service benchmarking
9.1.3.3 Strategic initiatives
9.1.4 Catalent, Inc
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Service benchmarking
9.1.5 Siegfried Holding AG
9.1.5.1 Company overview
9.1.5.2 Financial performance
9.1.5.3 Service benchmarking
9.1.5.4 Strategic initiatives
9.1.6 Recipharm AB
9.1.6.1 Company overview
9.1.6.2 Financial performance
9.1.6.3 Service benchmarking
9.1.6.4 Strategic initiatives
9.1.7 CordenPharma International
9.1.7.1 Company overview
9.1.7.2 Service benchmarking
9.1.7.3 Strategic initiatives
9.1.8 Boehringer ingelheim
9.1.8.1 Company overview
9.1.8.2 Financial performance
9.1.8.3 Service benchmarking
9.1.8.4 Strategic initiatives
9.1.9 Piramal Pharma Solutions
9.1.9.1 Company overview
9.1.9.2 Financial performance
9.1.9.3 Service benchmarking
9.1.9.4 Strategic initiatives
9.1.10 Labcorp Drug Development
9.1.10.1 Company overview
9.1.10.2 Financial performance
9.1.10.3 Service benchmarking
9.1.10.4 Strategic initiatives
9.2 Company Analysis
9.2.1 Heat Map Analysis of Competitors
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Stage Type
1.1.3 Customer Type
1.1.4 Therapeutic Area
1.1.5 Regional Scope
1.1.6 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.5.1 Approaches Used To Estimate The Market Size
1.5.1.1 Approach 1: Region-Wise Market Estimation Using Bottom-Up Approach
1.5.1.2 Approach 2: Parent Market Analysis
1.5.1.3 Approach 3: Commodity Flow (Company Share Analysis)
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 OBJECTIVE - 1:
1.9.2 OBJECTIVE - 2:
1.9.3 OBJECTIVE - 3:
1.9.4 OBJECTIVE - 4:
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Segment Outlook
CHAPTER 3 SMALL MOLECULE INNOVATORS CDMO MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing Demand for Small Molecule Drug
3.2.1.2 Growing Demand for Small Molecules in the Oncology Segment
3.2.1.3 Increasing Pharmaceutical R&D Investments
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent Government Regulations
3.3.2.2 Compliance Issues with Outsourcing
3.3 Small Molecule Innovators CDMO Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTEL Analysis
3.4 Impact of COVID-19 and Reformation Strategies
CHAPTER 4 SMALL MOLECULE INNOVATOR CDMO MARKET: PRODUCT SEGMENT ANALYSIS
4.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
4.2 Small Molecule API
4.2.1 Small Molecule API, 2018 - 2030 (USD Million)
4.3 Small Molecule Drug Product
4.3.1 Small Molecule Drug Product Market, 2018 - 2030 (USD Billion)
4.3.2 Oral Solid Dose
4.3.2.1 Oral Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.3 Semi-Solid Dose
4.3.3.1 Semi-Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.4 Liquid Dose
4.3.4.1 Liquid-Solid Dose Market, 2018 - 2030 (USD Billion)
4.3.5 Others
4.3.5.1 Others Market, 2018 - 2030 (USD Billion)
CHAPTER 5 SMALL MOLECULE INNOVATORS CDMO MARKET: STAGE TYPE SEGMENT ANALYSIS
5.1 Small Molecule Innovators Cdmo: Market Share Analysis, 2022 & 2030
5.2 Preclinical
5.2.1 Preclinical Market, 2018 - 2030 (USD Billion)
5.3 Clinical
5.3.1 Clinical Market, 2018 - 2030 (USD Billion)
5.3.2 Phase I
5.3.2.1 Phase I Market, 2018 - 2030 (USD Billion)
5.3.2.2 Small
5.3.2.2.1 Small Market, 2018 - 2030 (USD Billion)
5.3.2.3 Medium
5.3.2.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.2.4 Large
5.3.2.4.1. Large Market, 2018 - 2030 (USD Billion)
5.3.3 Phase II
5.3.3.1 Phase II Market, 2018 - 2030 (USD Billion)
5.3.3.2 Small
5.3.3.2.1. Small Market, 2018 - 2030 (USD Billion)
5.3.3.3 Medium
5.3.3.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.3.4 Large
5.3.3.4.1. Large Market, 2018 - 2030 (USD Billion)
5.3.4 Phase III
5.3.4.1 Phase III Market, 2018 - 2030 (USD Billion)
5.3.4.2 Small
5.3.4.2.1 Small Market, 2018 - 2030 (USD Billion)
5.3.4.3 Medium
5.3.4.3.1. Medium Market, 2018 - 2030 (USD Billion)
5.3.4.4 Large
5.3.4.4.1. Large Market, 2018 - 2030 (USD Billion)
5.4 Commercial
5.4.1. Commercial Market, 2018 - 2030 (USD Billion)
CHAPTER 6 SMALL MOLECULE INNOVATORS CDMO MARKET: CUSTOMER TYPE SEGMENT ANALYSIS
6.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
6.2 Pharmaceutical
6.2.1 Pharmaceutical Market, 2018 - 2030 (USD Million)
6.2.2 Small
6.2.2.1 Small Market, 2018 - 2030 (USD Million)
6.2.3 Medium
6.2.3.1 Medium Market, 2018 - 2030 (USD Million)
6.2.4 Large
6.2.4.1 Large Market, 2018 - 2030 (USD Million)
6.3 Biotechnology
6.3.1 Biotechnology Market, 2018 - 2030 (USD Million)
CHAPTER 7 SMALL MOLECULE INNOVATORS CDMO MARKET: THERAPEUTIC AREA SEGMENT ANALYSIS
7.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
7.2 Cardiovascular Disease
7.2.1 Cardiovascular diseases market, 2018 - 2030 (USD Million)
7.3 Oncology
7.3.1 Oncology market, 2018 - 2030 (USD Million)
7.4 Respiratory Disorders
7.4.1 Respiratory disorders market, 2018 - 2030 (USD Million)
7.5 Neurology
7.5.1 Neurology market, 2018 - 2030 (USD Million)
7.6 Metabolic Disorders
7.6.1 Metabolic disorders market, 2018 - 2030 (USD Million)
7.7 Infectious Diseases
7.7.1 Infectious diseases market, 2018 - 2030 (USD Million)
7.8 Others
7.8.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 8 SMALL MOLECULE INNOVATORS CDMO MARKET: REGIONAL ANALYSIS
8.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
8.2 North America
8.2.1 North America Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3 Europe
8.3.1 Europe Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.2 U.K.
8.3.2.1 U.K. Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.3 Germany
8.3.3.1 Germany Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.4 France
8.3.4.1 France Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.5 Italy
8.3.5.1 Italy Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.6 Spain
8.3.6.1 Spain Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.7 Denmark
8.3.7.1 Denmark Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.8 Sweden
8.3.8.1 Sweden Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.3.9 Norway
8.3.9.1 Norway Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.2 India
8.4.2.1 India Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.3 Japan
8.4.3.1 Japan Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.4 China
8.4.4.1 China Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.5 Australia
8.4.5.1 Australia Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.6 South Korea
8.4.6.1 South Korea Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.4.7 Thailand
8.4.7.1 Thailand Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5 Latin America
8.5.1 Latin America Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Argentina Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6 MEA
8.6.1 MEA Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.4 UAE
8.6.4.1 UAE Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
8.6.5 Kuwait
8.6.5.1 Kuwait Small Molecule Innovators CDMO market, 2018 - 2030 (USD Million)
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Company Profiles
9.1.1 Lonza
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Service benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Patheon (Thermo Fisher Scientific)
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Service benchmarking
9.1.2.4 Strategic initiatives
9.1.3 Cambrex Corporation
9.1.3.1 Company overview
9.1.3.2 Service benchmarking
9.1.3.3 Strategic initiatives
9.1.4 Catalent, Inc
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Service benchmarking
9.1.5 Siegfried Holding AG
9.1.5.1 Company overview
9.1.5.2 Financial performance
9.1.5.3 Service benchmarking
9.1.5.4 Strategic initiatives
9.1.6 Recipharm AB
9.1.6.1 Company overview
9.1.6.2 Financial performance
9.1.6.3 Service benchmarking
9.1.6.4 Strategic initiatives
9.1.7 CordenPharma International
9.1.7.1 Company overview
9.1.7.2 Service benchmarking
9.1.7.3 Strategic initiatives
9.1.8 Boehringer ingelheim
9.1.8.1 Company overview
9.1.8.2 Financial performance
9.1.8.3 Service benchmarking
9.1.8.4 Strategic initiatives
9.1.9 Piramal Pharma Solutions
9.1.9.1 Company overview
9.1.9.2 Financial performance
9.1.9.3 Service benchmarking
9.1.9.4 Strategic initiatives
9.1.10 Labcorp Drug Development
9.1.10.1 Company overview
9.1.10.2 Financial performance
9.1.10.3 Service benchmarking
9.1.10.4 Strategic initiatives
9.2 Company Analysis
9.2.1 Heat Map Analysis of Competitors
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 1 List of secondary sources
Table 2 List of abbreviations
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Small Molecule Innovators CDMO market snapshot (2020) (USD Million)
Fig. 9 Small Molecule Innovator market segmentation
Fig. 10 Parent market outlook
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Porter’s five forces analysis
Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 16 Small Molecule Innovator CDMO market Product outlook: Segment dashboard
Fig. 17 Small Molecule Innovators CDMO market: Product movement analysis
Fig. 18 Small Molecule API market 2018 - 2030 (USD Million)
Fig. 19 Small Molecule Drug Product Market, 2018 - 2030 (USD Million)
Fig. 20 Oral solid dose Market, 2018 - 2030 (USD Million)
Fig. 21 Semi-solid Dose Market, 2018 - 2030 (USD Million)
Fig. 22 Semi-Solid Dose Market, 2018 - 2030 (USD Million)
Fig. 23 Antibody-drug conjugate market, 2018 - 2030 (USD Million)
Fig. 24 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 25 Small Molecule Innovators CDMO market: Stage type movement analysis
Fig. 26 Preclinical market, 2018 - 2030 (USD Million)
Fig. 27 Clinical market, 2018 - 2030 (USD Million)
Fig. 28 Phase I market, 2018 - 2030 (USD Million)
Fig. 29 Small market, 2018 - 2030 (USD Million)
Fig. 30 Medium market, 2018 - 2030 (USD Million)
Fig. 31 Large market, 2018 - 2030 (USD Million)
Fig. 32 Phase II market, 2018 - 2030 (USD Million)
Fig. 33 Small market, 2018 - 2030 (USD Million)
Fig. 34 Medium market, 2018 - 2030 (USD Million)
Fig. 35 Large market, 2018 - 2030 (USD Million)
Fig. 36 Phase III market, 2018 - 2030 (USD Million)
Fig. 37 Small market, 2018 - 2030 (USD Million)
Fig. 38 Medium market, 2018 - 2030 (USD Million)
Fig. 39 Large market, 2018 - 2030 (USD Million)
Fig. 40 Commercial market, 2018 - 2030 (USD Million)
Fig. 41 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 42 Small Molecule Innovators CDMO market: Customer type movement analysis
Fig. 43 Pharmaceutical market, 2018– 2030 (USD Million)
Fig. 44 Small market, 2018 - 2030 (USD Million)
Fig. 45 Medium market, 2018 - 2030 (USD Million)
Fig. 46 Large market, 2018 - 2030 (USD Million)
Fig. 47 Biotechnology market, 2018 - 2030 (USD Million)
Fig. 48 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 49 Small Molecule Innovators CDMO market: Therapeutic area movement analysis
Fig. 50 Cardiovascular Disease market, 2018 - 2030 (USD Million)
Fig. 51 Oncology market, 2018 - 2030 (USD Million)
Fig. 52 Respiratory Disorders market, 2018 - 2030 (USD Million)
Fig. 53 Neurology market, 2018 - 2030 (USD Million)
Fig. 54 Metabolic disorders market, 2018 - 2030 (USD Million)
Fig. 55 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 56 Other’s market, 2018 - 2030 (USD Million)
Fig. 57 Regional market: Key takeaways
Fig. 58 Small Molecule Innovators CDMO market: Regional movement analysis
Fig. 59 North America market, 2018 - 2030 (USD Million)
Fig. 60 U.S. market, 2018 - 2030 (USD Million)
Fig. 61 Canada market, 2018 - 2030 (USD Million)
Fig. 62 Europe market, 2018 - 2030 (USD Million)
Fig. 63 U.K. market, 2018 - 2030 (USD Million)
Fig. 64 Germany market, 2018 - 2030 (USD Million)
Fig. 65 France market, 2018 - 2030 (USD Million)
Fig. 66 Italy market, 2018 - 2030 (USD Million)
Fig. 67 Spain market, 2018 - 2030 (USD Million)
Fig. 68 Denmark market, 2018 - 2030 (USD Million)
Fig. 69 Sweden market, 2018 - 2030 (USD Million)
Fig. 70 Norway market, 2018 - 2030 (USD Million)
Fig. 72 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 73 India market, 2018 - 2030 (USD Million)
Fig. 74 Japan market, 2018 - 2030 (USD Million)
Fig. 75 China market, 2018 - 2030 (USD Million)
Fig. 76 Australia market, 2018 - 2030 (USD Million)
Fig. 77 South Korea market, 2018 - 2030 (USD Million)
Fig. 78 Thailand market, 2018 - 2030 (USD Million)
Fig. 79 Latin America market, 2018 - 2030 (USD Million)
Fig. 80 Brazil market, 2018 - 2030 (USD Million)
Fig. 81 Mexico market, 2018 - 2030 (USD Million)
Fig. 82 Argentina market, 2018 - 2030 (USD Million)
Fig. 83 MEA market, 2018 - 2030 (USD Million)
Fig. 84 South Africa market, 2018 - 2030 (USD Million)
Fig. 85 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 86 UAE market, 2018 - 2030 (USD Million)
Fig. 87 Kuwait market, 2018 - 2030 (USD Million)
Fig. 88 Heat Map Analysis
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Small Molecule Innovators CDMO market snapshot (2020) (USD Million)
Fig. 9 Small Molecule Innovator market segmentation
Fig. 10 Parent market outlook
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Porter’s five forces analysis
Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 16 Small Molecule Innovator CDMO market Product outlook: Segment dashboard
Fig. 17 Small Molecule Innovators CDMO market: Product movement analysis
Fig. 18 Small Molecule API market 2018 - 2030 (USD Million)
Fig. 19 Small Molecule Drug Product Market, 2018 - 2030 (USD Million)
Fig. 20 Oral solid dose Market, 2018 - 2030 (USD Million)
Fig. 21 Semi-solid Dose Market, 2018 - 2030 (USD Million)
Fig. 22 Semi-Solid Dose Market, 2018 - 2030 (USD Million)
Fig. 23 Antibody-drug conjugate market, 2018 - 2030 (USD Million)
Fig. 24 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 25 Small Molecule Innovators CDMO market: Stage type movement analysis
Fig. 26 Preclinical market, 2018 - 2030 (USD Million)
Fig. 27 Clinical market, 2018 - 2030 (USD Million)
Fig. 28 Phase I market, 2018 - 2030 (USD Million)
Fig. 29 Small market, 2018 - 2030 (USD Million)
Fig. 30 Medium market, 2018 - 2030 (USD Million)
Fig. 31 Large market, 2018 - 2030 (USD Million)
Fig. 32 Phase II market, 2018 - 2030 (USD Million)
Fig. 33 Small market, 2018 - 2030 (USD Million)
Fig. 34 Medium market, 2018 - 2030 (USD Million)
Fig. 35 Large market, 2018 - 2030 (USD Million)
Fig. 36 Phase III market, 2018 - 2030 (USD Million)
Fig. 37 Small market, 2018 - 2030 (USD Million)
Fig. 38 Medium market, 2018 - 2030 (USD Million)
Fig. 39 Large market, 2018 - 2030 (USD Million)
Fig. 40 Commercial market, 2018 - 2030 (USD Million)
Fig. 41 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 42 Small Molecule Innovators CDMO market: Customer type movement analysis
Fig. 43 Pharmaceutical market, 2018– 2030 (USD Million)
Fig. 44 Small market, 2018 - 2030 (USD Million)
Fig. 45 Medium market, 2018 - 2030 (USD Million)
Fig. 46 Large market, 2018 - 2030 (USD Million)
Fig. 47 Biotechnology market, 2018 - 2030 (USD Million)
Fig. 48 Small Molecule Innovators CDMO market synthesis outlook: segment dashboard
Fig. 49 Small Molecule Innovators CDMO market: Therapeutic area movement analysis
Fig. 50 Cardiovascular Disease market, 2018 - 2030 (USD Million)
Fig. 51 Oncology market, 2018 - 2030 (USD Million)
Fig. 52 Respiratory Disorders market, 2018 - 2030 (USD Million)
Fig. 53 Neurology market, 2018 - 2030 (USD Million)
Fig. 54 Metabolic disorders market, 2018 - 2030 (USD Million)
Fig. 55 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 56 Other’s market, 2018 - 2030 (USD Million)
Fig. 57 Regional market: Key takeaways
Fig. 58 Small Molecule Innovators CDMO market: Regional movement analysis
Fig. 59 North America market, 2018 - 2030 (USD Million)
Fig. 60 U.S. market, 2018 - 2030 (USD Million)
Fig. 61 Canada market, 2018 - 2030 (USD Million)
Fig. 62 Europe market, 2018 - 2030 (USD Million)
Fig. 63 U.K. market, 2018 - 2030 (USD Million)
Fig. 64 Germany market, 2018 - 2030 (USD Million)
Fig. 65 France market, 2018 - 2030 (USD Million)
Fig. 66 Italy market, 2018 - 2030 (USD Million)
Fig. 67 Spain market, 2018 - 2030 (USD Million)
Fig. 68 Denmark market, 2018 - 2030 (USD Million)
Fig. 69 Sweden market, 2018 - 2030 (USD Million)
Fig. 70 Norway market, 2018 - 2030 (USD Million)
Fig. 72 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 73 India market, 2018 - 2030 (USD Million)
Fig. 74 Japan market, 2018 - 2030 (USD Million)
Fig. 75 China market, 2018 - 2030 (USD Million)
Fig. 76 Australia market, 2018 - 2030 (USD Million)
Fig. 77 South Korea market, 2018 - 2030 (USD Million)
Fig. 78 Thailand market, 2018 - 2030 (USD Million)
Fig. 79 Latin America market, 2018 - 2030 (USD Million)
Fig. 80 Brazil market, 2018 - 2030 (USD Million)
Fig. 81 Mexico market, 2018 - 2030 (USD Million)
Fig. 82 Argentina market, 2018 - 2030 (USD Million)
Fig. 83 MEA market, 2018 - 2030 (USD Million)
Fig. 84 South Africa market, 2018 - 2030 (USD Million)
Fig. 85 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 86 UAE market, 2018 - 2030 (USD Million)
Fig. 87 Kuwait market, 2018 - 2030 (USD Million)
Fig. 88 Heat Map Analysis
